Antimicrobial Treatment of Lower Respiratory Tract Infections

Guest Editors:

Prof. Dr. Anastasia Kotanidou

Prof. Dr. Sotirios Tsiodras

Dr. Paraskevi C. Fragkou

Dr. Charalampos D. Moschopoulos

Deadline for manuscript submissions:
30 June 2024

Message from the Guest Editors

Dear Colleagues,

This Special Issue aims to delineate the latest pre-clinical (experimental), animal and clinical research and clinic-epidemiological data on the role of old and newer antimicrobials in the progress, prognosis and the outcome of pneumonia. Ultimately, this issue aims to expand our understanding and generate in-depth knowledge on the management of community- and healthcare-associated bacterial LRTIs through gathering current evidence and addressing potential gaps in the literature.

Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: antimicrobial treatment in community-acquired pneumonia/lower respiratory tract infection; antimicrobial treatment in healthcare-associated pneumonia; epidemiology and mechanisms of antibiotic resistance of pneumonia pathogens; novel antibiotics for lower respiratory tract infections; use of antimicrobials for lower respiratory tract infections in specific populations, such as immunocompromised and critically ill patients, those with COVID-19 and other severe viral LRTIs and elderly, pediatric, cystic fibrosis, COPD and asthma patients.

mdpi.com/si/136437

SpecialIssue

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us